108303-53-3

Usage

Explanation

Isosafrole is an alternative name for 1,3-Benzodioxole,5-(1-methylethyl)-(9CI), which is used to describe the compound more easily.

Explanation

The compound exists in a liquid state at room temperature, and it is both clear and colorless, meaning it does not have any visible color or opacity.

Explanation

Isosafrole has a strong, sharp, and unpleasant smell, which is described as pungent.

Explanation

Isosafrole is used in the production of various products, including fragrances, additives for the food industry, and components in the pharmaceutical industry.

Explanation

Isosafrole serves as a starting material or precursor in the chemical synthesis of MDMA, an illegal psychoactive drug.

Explanation

The International Agency for Research on Cancer (IARC) has classified isosafrole as a potential carcinogen, meaning it has the ability to cause cancer in humans or animals.

Explanation

Due to its potential health and environmental risks, the use of isosafrole is regulated in several countries to minimize exposure and mitigate potential hazards.

Physical state

Clear, colorless liquid

Odor

Pungent

Applications

Perfumes, flavorings, and pharmaceuticals

Precursor

Synthesis of MDMA (ecstasy)

Carcinogenicity

Potential carcinogen (IARC classification)

Regulatory status

Use regulated in many countries

Upstream product

• 119055-67-3 5-(prop-1-en-2-yl)benzo[d][1,3]dioxole 
• 64-17-5 ethanol 
• 3162-29-6 1-(benzo[d][1,3]dioxol-6-yl)ethanone 
• 7228-38-8 5-chloro-1,3-benzodioxole 
• 1068-55-9 isopropylmagnesium chloride 

Downstream Products

• 2138-43-4 4-isopropylcatechol 

Relevant academic research and scientific papers

Iron-Catalyzed Isopropylation of Electron-Deficient Aryl and Heteroaryl Chlorides

Traditional methods for the preparation of secondary alkyl-substituted aryl and heteroaryl chlorides challenge both selectivity and functional group tolerance. This contribution describes the use of statistical design of experiments to develop an effective procedure for the preparation of isopropyl-substituted (hetero)arenes with minimal isopropyl to n-propyl isomerization. The reaction tolerates electronically diverse aryl chloride coupling partners, with excellent conversion observed for strongly electron-deficient aromatic rings, such as esters and amides. Electron-rich systems, including methyl- and methoxy-substituted aryl chlorides, were found to be less reactive. Furthermore, the reaction was found to be most successful when heteroaryl chlorides were submitted to the cross-coupling protocol. By mapping substituent effects on reaction selectivity, we were able to show that electron-deficient aryl chlorides are essential for efficient coupling, and use electronic structure calculations to predict the likelihood of successful coupling through the estimation of the electron affinity of each aryl chloride. Moderate isolated yields were achieved with selected aryl chlorides, and moderate to good isolated yields were obtained for all the heteroaryl chlorides coupled. Excellent selectivity was observed when a 2,6-dichloroquinoline was used, allowing mono-substitution on a challenging substrate. (Figure presented.).

COMPOUNDS AS HSP90 INHIBITORS

The invention provides novel compounds of formula (I) wherein: one of the a, b, c or d members is a nitrogen atom and the remaining members are carbon atoms; and R3 is a radical selected from the group consisting of: —S—R14 and —CH2—R15. The compounds of formula (I) are useful for treating diseases mediated by a heat shock protein 90 (Hsp 90)

Reductive one-carbon homologation of aldehydes and ketones

A rhodium-catalyzed methylenation-hydrogenation cascade process allows the homologation of carbonyl compounds to lead to the corresponding alkanes in high yields.

2-SACCHARINYLMETHYL PHOSPHATES, PHOSPHONATES AND PHOSPHINATES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND COMPOSITIONS AND METHOD OF USE THEREOF

4-R 1-R 2-R 3-2-Saccharinylmethyl and 4,7-C-4,5, 6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates of formulas I and IIA respectively herein, useful in the treatment of degenerative diseases, and compositions containing them, methods for using them to treat degenerative diseases, and processes for their preparation by reaction of the corresponding 2-halomethylsaccharins with a phosphate, phosphonate or phosphinic acid of formula III herein in the presence of an acid-acceptor.

2-SACCHARINYLMETHYL AND 4,5,6,7-TETRAHYDRO-2-SACCHARINYLMETHYL PHOSPHATES, PHOSPHONATES AND PHOSPHINATES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND COMPOSITIONS AND METHOD OF USE THEREOF

4-R 1-R 2-R 3-2-Saccharinylmethyl, 4-R 4-4-R 5-6-R 6-4,5,6,7-tetrahydro-2-saccharinylmethyl and 4,7-C-4,5, 6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates of formulas I, II and IIA respectively herein, useful in the treatment of degenerative diseases, and compositions containing them, methods for using them to treat degenerative diseases, and processes for their preparation by reaction of the corresponding 2-halomethylsaccharins with a phosphate, phosphonate or phosphinic acid of formula III herein in the presence of an acid-acceptor.